HELSINKI, Finland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany™s...
HELSINKI, Finland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it is the first biotech company in Europe...
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its phase 1 clinical study. ValoTx’s PeptiCRAd-1 combines the power of a tumour-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumour peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumour-specific, cytotoxic T-cells that will attack and kill cancer cells.
HELSINKI, Finland and EVRY, France, June 13, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with...
HELSINKI, Finland, May 23, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in...
Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced four...
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, announces the exclusive...